FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
FibroBiologics (Nasdaq: FBLG) has been granted a patent by the European Patent Office for a novel cancer treatment method using modified fibroblasts to deliver anti-cancer agents. The patent (Number 19795975.2) covers methods and compositions for enhancing fibroblasts' ability to target cancerous tissues and deliver tumor-inhibiting agents directly to cancer cells.
This innovative approach aims to improve the effectiveness of cancer treatments by leveraging fibroblasts' natural ability to penetrate tumor tissues and modulate immune responses. The technology could potentially address challenges faced by traditional therapies, such as tumor penetration, and may offer new possibilities for treating primary, metastatic, and treatment-resistant tumors.
FibroBiologics (Nasdaq: FBLG) ha ricevuto un brevetto dall'Ufficio Europeo dei Brevetti per un nuovo metodo di trattamento del cancro che utilizza fibroblasti modificati per somministrare agenti anti-cancro. Il brevetto (Numero 19795975.2) copre metodi e composizioni per migliorare la capacità dei fibroblasti di mirare ai tessuti cancerosi e di consegnare agenti inibitori dei tumori direttamente alle cellule tumorali.
Questo approccio innovativo mira a migliorare l'efficacia dei trattamenti contro il cancro sfruttando la capacità naturale dei fibroblasti di penetrare nei tessuti tumorali e modulare le risposte immunitarie. La tecnologia potrebbe affrontare le sfide incontrate dalle terapie tradizionali, come la penetrazione nei tumori, e potrebbe offrire nuove possibilità per trattare tumori primari, metastatici e resistenti ai trattamenti.
FibroBiologics (Nasdaq: FBLG) ha recibido una patente de la Oficina Europea de Patentes para un nuevo método de tratamiento del cáncer que utiliza fibroblastos modificados para administrar agentes anticancerígenos. La patente (Número 19795975.2) cubre métodos y composiciones para mejorar la capacidad de los fibroblastos para atacar los tejidos cancerosos y entregar agentes inhibidores de tumores directamente a las células cancerosas.
Este enfoque innovador tiene como objetivo mejorar la efectividad de los tratamientos contra el cáncer aprovechando la habilidad natural de los fibroblastos para penetrar en los tejidos tumorales y modular las respuestas inmunitarias. La tecnología podría abordar los desafíos enfrentados por las terapias tradicionales, como la penetración del tumor, y podría ofrecer nuevas posibilidades para tratar tumores primarios, metastásicos y resistentes al tratamiento.
FibroBiologics (Nasdaq: FBLG)는 유럽 특허청으로부터 수정된 섬유아세포를 사용하여 항암제를 전달하는 혁신적인 암 치료 방법에 대한 특허를 부여받았습니다. 이 특허(번호 19795975.2)는 섬유아세포가 암 조직을 표적하고 종양 억제제를 암 세포에 직접 전달하는 능력을 향상시키는 방법 및 조성을 포함합니다.
이 혁신적인 접근 방식은 섬유아세포의 자연적인 종양 조직 침투 및 면역 반응 조절 능력을 활용하여 암 치료의 효율성을 개선하는 것을 목표로 하고 있습니다. 이 기술은 종양 침투와 같은 전통적인 치료가 직면한 문제들을 해결할 수 있으며, 원발성, 전이성 및 치료 저항성 종양을 치료하는 새로운 가능성을 제공합니다.
FibroBiologics (Nasdaq: FBLG) a obtenu un brevet de l'Office Européen des Brevets pour une nouvelle méthode de traitement du cancer utilisant des fibroblastes modifiés pour délivrer des agents anticancéreux. Le brevet (Numéro 19795975.2) couvre des méthodes et des compositions visant à améliorer la capacité des fibroblastes à cibler les tissus cancéreux et à délivrer directement des agents inhibiteurs de tumeur aux cellules cancéreuses.
Cette approche innovante vise à améliorer l'efficacité des traitements contre le cancer en s'appuyant sur la capacité naturelle des fibroblastes à pénétrer les tissus tumoraux et à moduler les réponses immunitaires. La technologie pourrait potentiellement résoudre les défis auxquels font face les thérapies traditionnelles, telles que la pénétration dans la tumeur, et pourrait offrir de nouvelles possibilités pour traiter des tumeurs primaires, métastatiques et résistantes aux traitements.
FibroBiologics (Nasdaq: FBLG) hat vom Europäischen Patentamt ein Patent für ein neuartiges Krebsbehandlungsverfahren erhalten, das modifizierte Fibroblasten zur Abgabe von Anti-Krebs-Mitteln verwendet. Das Patent (Nummer 19795975.2) umfasst Methoden und Zusammensetzungen zur Verbesserung der Fähigkeit von Fibroblasten, krebskranke Gewebe anzuvisieren und Tumorinhibitoren direkt an Krebszellen abzugeben.
Dieser innovative Ansatz zielt darauf ab, die Wirksamkeit von Krebsbehandlungen zu verbessern, indem er die natürliche Fähigkeit der Fibroblasten nutzt, in Tumorgewebe einzudringen und Immunantworten zu modulieren. Die Technologie könnte potenziell Herausforderungen angehen, mit denen herkömmliche Therapien konfrontiert sind, wie z.B. die Eindringtiefe im Tumor, und könnte neue Möglichkeiten zur Behandlung von primären, metastatischen und therapieresistenten Tumoren bieten.
- Issuance of a new patent in Europe, expanding intellectual property portfolio
- Potential for improved cancer treatment delivery using modified fibroblasts
- Possible advantage over traditional therapies in tumor penetration
- None.
Insights
This patent issuance represents a significant advancement in cancer treatment technology, potentially revolutionizing drug delivery methods. The use of modified fibroblasts as delivery vehicles for anti-cancer agents addresses a critical challenge in oncology: effective drug penetration into tumor tissues.
Key advantages of this approach include:
- Enhanced targeting of cancer cells due to fibroblasts' natural affinity for tumor microenvironments
- Potential for improved efficacy against primary, metastatic and treatment-resistant tumors
- Possible reduction in systemic side effects by localizing treatment delivery
While promising, it's important to note that this is still a preclinical technology. The path from patent to marketable treatment is long and uncertain, requiring extensive clinical trials to prove safety and efficacy. Investors should view this as a long-term prospect rather than an immediate revenue generator.
The patent strengthens FibroBiologics' intellectual property portfolio, potentially increasing the company's value and attractiveness for partnerships or acquisitions in the oncology space. However, the true commercial impact will depend on successful development and regulatory approval of therapies based on this technology.
This patent issuance bolsters FibroBiologics' intellectual property portfolio, potentially enhancing the company's long-term value proposition. With a market cap of
Key financial implications:
- Increased potential for licensing agreements or partnerships, generating future revenue streams
- Enhanced attractiveness for merger and acquisition activities
- Possible increase in R&D expenses as the company develops this technology
Investors should note that while patents are valuable, they don't guarantee commercial success. The time and capital required to bring this technology to market are substantial and FibroBiologics will likely need additional funding rounds or partnerships to support development.
The company's broad patent portfolio (
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of a patent from the European Patent Office (Patent Number 19795975.2) covering methods and compositions for the treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual.
This method uses modified fibroblasts to deliver tumor-inhibiting agents directly to cancer cells. The fibroblasts would be engineered to enhance their natural ability to target cancerous tissues, and then loaded with therapeutic agents to fight primary, metastatic, or treatment-resistant tumors. Modifying the fibroblasts in this manner may make them more effective in targeting cancer cells and delivering treatment.
Founder & Chief Executive Officer of FibroBiologics, Pete O’Heeron said, “The issuance of this patent recognizes the novelty and utility of using modified fibroblasts to deliver tumor-inhibiting agents for cancer treatment. This technology is an example of the potential therapeutic versatility of fibroblast cell-based therapies.”
Chief Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D., added, “This patent is yet another major milestone for a potential cancer treatment platform. Traditional therapies often struggle with limited penetration into tumor tissues, but fibroblasts may offer a significant advantage as they are a key component of the tumor microenvironment and have the ability to modulate the immune response. By harnessing the unique characteristics of fibroblasts, we may be able to deliver tumor-inhibiting agents more effectively, potentially opening new avenues for targeting even the most challenging cancer types.”
For more information, please visit FibroBiologics’ website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of fibroblasts to effectively deliver tumor-inhibiting agents directly to cancer cells, offer a significant advantage as they are a key component of the tumor microenvironment and have the ability to modulate the immune response, and offer clinical benefits for patients. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What patent did FibroBiologics (FBLG) receive from the European Patent Office?
How does FibroBiologics' (FBLG) new patented cancer treatment method work?
What advantage does FibroBiologics' (FBLG) fibroblast-based cancer treatment offer over traditional therapies?
